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PENILAIAN KUALITI HIDUP, EKONOMI DAN KLINIKAL DALAM 
KALANGAN PESAKIT SKIZOFRENIA DI PUSAT PERUBATAN 
UNIVERSITI KEBANGSAAN MALAYSIA   
 
ABSTRAK 
Skizofrenia merupakan penyakit mental kronik dan serius yang bermula pada awal 
remaja dan berterusan sepanjang hayat. Ia mendatangkan kesan ke atas aspek 
peribadi, sosial dan ekonomi pesakit, keluarga dan masyarakat pada amnya. Objektif 
kajian ini adalah bagi menentukan dan membandingkan impak kualiti hidup, 
ekonomi dan klinikal di kalangan pesakit skizofrenia yang menerima rawatan 
dengan berlainan kumpulan antipsikotik selama setahun. Kajian ini adalah kajian 
pengamatan dan prospektif. Pesakit dibahagikan kepada 2 kumpulan iaitu kumpulan 
atipikal dan tipikal antipsikotik. Pesakit dinilai pada permulaan kajian, 3, 6 dan 12 
bulan. Kualiti hidup pesakit dinilai menggunakan instrumen kualiti hidup spesifik 
iaitu ’Schizophrenia Quality of Life Scale Revision 4’ (SQLS-R4) dan instrumen 
kualiti hidup generik iaitu ’EuroQoL Group EQ-5D’. Kesan klinikal dinilai 
menggunakan instrumen ’Clinical Global Impressions-Schizophrenia’ (CGI-SCH) 
untuk simptom penyakit, ’Approaches to Schizophrenia Communication Clinician 
Interview Version’ (ASC-C) untuk kesan sampingan antipsikotik dan rekod 
pengisian preskripsi untuk kepatuhan terhadap pengambilan antipsikotik. Analisis 
keberkesanan kos dan analisis kos utiliti dikira untuk setiap kumpulan antipsikotik. 
Nisbah keberkesan kos tambahan agen antipsikotik atipikal dibandingkan dengan 
agen antipsikotik tipikal. Terdapat 159 pesakit yang kekal dalam kajian. Pesakit 
dalam kumpulan antipsikotik atipikal lebih muda, kebanyakkannya bujang dan 
mempunyai tahap akademik yang lebih tinggi berbanding dengan pesakit dalam 
 xx 
kumpulan antipsikotik tipikal. ’SQLS-R4’ merupakan instrumen kualiti hidup yang 
sah dan konsisten (nilai ’Cronbach’s ’ adalah 0.95 untuk subskala psikososial dan 
0.85 untuk subskala daya hidup; ‘item to total correlations’ dalam julat 0.45 ke 
0.70). Tiada perbezaan signifikan bagi purata skor keseluruhan ’SQLS-R4’ di antara 
kedua-dua kumpulan. Anggaran nisbah keberkesanan kos tambahan bagi agen 
antipsikotik atipikal dibandingkan dengan agen antipsikotik tipikal adalah RM85, 
575.44 setiap unit peningkatan skor keseluruhan ’CGI-SCH’ dan  RM770 179 setiap 
’QALY’ yang diperolehi. Nisbah keberkesan kos tambahan juga sensitif terhadap 
harga ubat antipsikotik. Tiada perbezaan dalam simptom keseluruhan penyakit di 
antara kedua-dua kumpulan. Keterukkan simptom menyumbang 25% kepada kualiti 
hidup. Kedua-dua kumpulan juga tidak berbeza dari segi kesan sampingan agen 
antipsikotik kecuali bagi masalah kabur penglihatan, masalah seksual dan masalah 
menstruasi/payudara. Pesakit dalam kumpulan ubat antipsikotik tipikal mempunyai 
kadar pengisian preskripsi antipsikotik yang lebih baik dan signifikan (79%) 
berbanding dengan pesakit dalam kumpulan ubat antipsikotik atipikal (70%). 
Rawatan dengan agen antipsikotik atipikal tidak menyumbang kepada perbezaan 
signifikan terhadap kualiti hidup, tahap simptom dan kebanyakkan kesan sampingan 
umum jika dibandingkan dengan agen antipsikotik tipikal. Ia juga merupakan 
strategi yang tidak kos efektif sekiranya tahap maksimum kesediaan untuk 
membayar bagi setiap ’QALY’ yang diperolehi adalah 3 kali ’Gross Domestic 
Product’ (GDP).      
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ASSESSMENT OF QUALITY OF LIFE, ECONOMIC AND CLINICAL 
OUTCOMES AMONG PATIENTS WITH SCHIZOPHRENIA IN 
UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTRE  
 
ABSTRACT 
Schizophrenia is a chronic and serious mental illness that occurs early and persists 
for a lifetime. It has significant personal, social & economic impact on the patients, 
families and society. The objective of the study was to determine and compare the 
impact of different types of antipsychotic maintenance treatment on humanistic, 
economic and clinical outcomes in routine clinical practice. The study was 
prospective and observational in nature. Patients were grouped into two treatment 
groups; atypical and typical treatment group and assessed at baseline, 3, 6 and 12 
months. Health-related quality of life (HRQoL) outcomes were assessed by disease 
specific scale, the Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4) and 
generic scale, the EuroQoL Group EQ-5D. Clinical outcomes were assessed using 
the Clinical Global Impressions-Schizophrenia (CGI-SCH) severity scale, the 
Approaches to Schizophrenia Communication Clinician Interview Version (ASC-C) 
side-effect checklist and prescription refills for antipsychotic adherence. Cost-
effectiveness analysis and cost-utility analysis were calculated for each treatment 
group. The incremental cost effectiveness (ICER) was determined for atypical 
antipsychotic relative to typical antipsychotic drug. There were 159 patients who 
completed the study. Patients on atypical antipsychotic treatment were younger, 
mainly single and tend to have higher academic qualifications than patients on 
typical antipsychotics. The SQLS-R4 was a valid and reliable HRQoL scale 
(Cronbach’s  = 0.95 and 0.85 for psychosocial and vitality subscale, respectively; 
 xxii 
item to total correlations ranged from 0.45 to 0.7). There was no significant 
difference in the mean SQLS-R4 overall scores between the treatment groups. The 
estimated adjusted ICER for atypical antipsychotics relative to typical antipsychotics 
was MYR85 575.44 per unit improved in CGI-SCH overall score and MYR770 179 
per QALY gained. The ICER was sensitive to acquisition costs of antipsychotic 
drugs. Overall symptom severity was not significantly different between the 2 
treatment groups. It contributed to 25% variation in the mean SQLS-R4 overall 
scores. There were no significant differences in side-effects between atypical and 
typical treatment groups except for blurred vision, sexual difficulties and menstrual 
irregularities/breast problem. Patients in the typical antipsychotic treatment group 
had significantly higher antipsychotic refills (79%) compared to atypical treatment 
group (70%). Treatment with atypical antipsychotics did not result in significant 
difference in HRQoL, symptom severity and most common-side effects compared to 
treatment with typical antipsychotics. It was not a cost-effective strategy than typical 
antipsychotic if the maximum willingness to pay for a QALY gained is 3 times the 
Gross Domestic Product (GDP).  
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 1 
CHAPTER 1 
 
GENERAL INTRODUCTION 
 
1.1  Epidemiology and Consequences of Schizophrenia 
 Schizophrenia is one of the most severe and disabling mental disorder that 
typically occurs in early adulthood and normally persists for a lifetime affecting 
patients’ quality of life and imposes immense burden on the society (Voruganti et 
al., 2000a). The condition is characterized by a varied symptom dimensions that 
includes positive symptoms (hallucinations, delusions), negative symptoms (flat 
affect, poverty of speech, decreased motivation, emotional and social withdrawal), 
disorganized symptoms (inappropriate affect, disorganized speech and behaviour), 
mood symptoms as well as various neurocognitive deficits (Awad et al., 1997a). 
There is wide variability in the course of schizophrenia, but generally its course is 
long-term following a mixed pattern of acute episodes of psychotic aggravations and 
periods of relatively well-balanced condition (Tunis et al., 2004). Absolute recovery 
from schizophrenia is infrequent. However, with advanced pharmacotherapy and 
appropriate psychosocial care nearly fifty percent of the patients initially diagnosed 
with schizophrenia would supposedly attained sustained remission from the illness 
(World Health Organization, 2001a).       
 The incidence of schizophrenia worldwide is comparatively low (15.2 per 
100,000 adults per year), but its prevalence is quite substantial (7.2 cases per 1000 
adults) owing to the chronic nature of the illness (Picchioni & Murray, 2007). It has 
been estimated that about 1% of the world population would be affected by 
schizophrenia at any time in their lifetime but the prevalence and incidence rates of 
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schizophrenia may vary across geographical areas (Awad & Voruganti, 2004a; 
McGrath et al., 2008). According to a recent analysis of three systematic reviews, 
the incidence rates of schizophrenia were higher in men compared to women 
(median ratio; 1.4: 1), among individuals who took up residence in the urban areas 
than those from rural or mixed urban-rural settings and among migrants versus the 
local residents (McGrath et al., 2008). Patients with schizophrenia also have a 
significantly higher mortality rate with two to threefold greater risks of death than 
the general public and reduced life expectancy approximately by an average of 10 
years (McGrath et al., 2008; Lindstrom et al., 2007a). The illness also contributes to 
higher risks of comorbidity with physical illness and other psychiatric syndromes 
(Knapp & Kavanagh, 1997). 
 In Malaysia, mental disorders account for 8.6% of the total disease burden 
and schizophrenia was the fourth highest burden among mental disorders (Chee, 
2009). The National Mental Health Registry (NMHR) was established by the 
Ministry of Health, Malaysia in 2003 and its initial priority was the schizophrenia 
registry to document the epidemiological data of schizophrenia and related psychotic 
disorders (Gill et al., 2005). Based on the NMHR report for the year 2003 to 2004, 
there were 2,467 new cases of schizophrenia registered in Malaysia with the 
majority being male (65%) and the ethnic composition of the cases reflected those of 
Malaysian population with Malays constitute the majority of the cases (53%) 
followed by patients of Chinese and Indian ethnicity; 27% and 9%, respectively 
(Gill et al., 2005). Most patients were also unmarried and without a job. 
 The personal, social and economic impact of schizophrenia upon patients, 
families and the common public are enormous (Voruganti et al., 2000a). 
Schizophrenia is among the top contributors to the global burden of disease and has 
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been estimated to account for 1.1% of the total disability-adjusted life years (DALY) 
lost due to all diseases and injuries and 2.8% of years of life lost due to disability 
(YLD) worldwide (Picchioni & Murray, 2007). Schizophrenia causes sufferings, 
disabilities and unfavourably affects quality of life in many areas of patient’s life 
functioning including physical and cognitive functioning as well as the ability to 
care for one self, maintain usual daily life activities, interact with others, establish 
relationships and acquire permanent employment (Knapp & Kavanagh, 1997). 
Families of the affected individuals also suffer a significant amount of distress in 
coping with their behaviours and burden in terms of productivity and time losses, 
and money spent on patient care (Essock et al., 2002). Additionally, it imposed costs 
on the society in terms of direct costs which involves monetary expenditure for 
therapy as well as indirect costs associated with lost productivity due to patient 
morbidity and mortality (Shaw, 2002).  
        Schizophrenia is a relatively expensive illness to treat. The lifetime prevalence 
of schizophrenia across populations is about 1.0%, but the resources utilized 
constitute 1.5 to 3.0% of the total healthcare budget (Geitona et al., 2008). As the 
condition occurs early in life and follows a chronic course, costs continued to be 
incurred for a long time leading to accumulation of direct costs from treatment and 
support, indirect costs of lost productivity and intangible costs of pain and sufferings 
due to reduced quality of life (Procyshyn et al., 2000). The direct costs of 
schizophrenia contributed 30-50% to overall costs with hospitalization accounting 
for a significant portion of direct medical costs (Rey, 2002). Indirect costs are 
difficult to quantify and often omitted from pharmacoeconomic analyses. 
Nonetheless, according to the latest studies the amount of indirect cost of 
schizophrenia is greater than the direct cost (Shaw, 2002). For instance, the 
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estimated total cost of treating schizophrenia in the United States for the year 1991 
was US$65.2 billion of which 70% of costs were attributed to indirect costs (Hudson 
et al., 2003). 
          
1.2 Treatment of Schizophrenia 
 The current modality of schizophrenia treatment involves a variety of 
interventions including pharmacological approach, rehabilitation and psychosocial 
therapy (Awad & Voruganti, 2004a). Drug treatment with antipsychotic medication 
however, is the principal component of clinical management of schizophrenia 
providing effective symptom control in acute and chronic phases of the disease 
(Lublin et al., 2004). Previously, the treatment of schizophrenia was non-specific 
and mainly physical which comprised social isolation, physical restraints, insulin 
coma and electroconvulsive therapy as well as a variety of occupational therapies 
involving agricultural work (Logan & Finley 1999; Deva, 2004). On the other hand, 
drug-based treatment like chloral hydrate or paraldehyde provides no antipsychotic 
effect but merely used to sedate and contain patients (Cancro, 2000).  
The serendipitous discovery of the first antipsychotic, chlorpromazine by the 
French anaesthesiologist and surgeon, Henri Leborit in the 1950s was a major 
landmark in the contemporary treatment of patients with schizophrenia and other 
psychotic disorders (Edlinger et al., 2005). Chlorpromazine not only reduces 
agitation and controls the overt positive symptoms of schizophrenia; it also 
facilitates the release of patients from the asylums enabling them to function fairly 
well in the society (Sawa & Snyder, 2002). In the next forty years, subsequent 
antipsychotic medications of similar dopamine D2-receptor-blocking activities as 
chlorpromazine like haloperidol and  perphenazine were developed and collectively 
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termed ‘neuroleptics’ or currently known as typical antipsychotic drugs due to 
linkage of its antipsychotic action and  extrapyramidal symptoms (EPS) (Lauriello 
& Bustillo, 2001). During that period of antipsychotic development, it was 
hypothesized that the event of EPS was crucial to achieving the therapeutic 
antipsychotic effects (Weiden, 2007). 
However, many patients approximately up to 60% of those treated had to 
endure disabling and upsetting acute extra-pyramidal side effects (EPS) including 
dystonic reactions (sudden onset of sustained intense muscle contraction), 
Parkinsonian-type symptoms, akathisia (restlessness) and at least 5% of the patients 
were inflicted by late-emerging tardive dyskinesia (irregular twisting or writhing 
movements), the most severe motor side-effects (Walker et al., 2004). The typical 
antipsychotics also do not relieve all symptoms, with their therapeutic properties 
confined mainly to the positive manifestations of the disease while being far less 
effective towards negative and neurocognitive symptoms (Lublin et al., 2005). Close 
to 60% of patients undergoing treatment with typical antipsychotics achieve full or 
partial remission of the positive symptoms, no less than 40% have unremitting or 
residual symptoms and further 20-30% of patients respond insufficiently to the 
medication with 15-20% relapsing each year (Singh, 2005; Gee et al., 2003).    
 The hypothesis that EPS was indispensable side effects of antipsychotics was 
re-considered when clozapine was found to have antipsychotic efficacy but 
negligible extra-pyramidal effects (Weiden, 2007). Clozapine was initially 
introduced to the European market in the 1960s but was soon withdrawn from sale 
following reports of rare but potentially fatal incidents of agranulocytosis (Shen, 
1999). It re-emerged in the 1980s following a landmark study that provided 
evidence of its superior efficacy and reduced EPS against chlorpromazine, steering 
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the development of successive antipsychotics that have similar benefits but without 
the risk of agranulocytosis and EPS (Remington, 2003).  
 The grouping of antipsychotic medication into ‘typical’ or ‘atypical’ to a 
certain extent is based on their in vivo occupancy of different receptors and the term 
‘atypical’ commonly refers to a new class of antipsychotic medication that has a 
lower risk of inducing severe neurological side effects known as  “extrapyramidal 
symptoms” (Lauriello & Bustillo, 2001). Clozapine and subsequent antipsychotics 
including risperidone, olanzapine, quetiapine and aripiprazole were referred as 
‘atypical antipsychotics’ as they have different pharmacological profile from the 
traditional antipsychotics with mostly have relatively lower affinity for dopamine 
D2 receptors and higher affinity for other neuroreceptors including serotonin 5-HT2 
receptors that may explained for their enhanced efficacy and reduced tendency for 
EPS (Miyamoto et al., 2005).    
Currently, in many developed nations, atypical antipsychotics other than 
clozapine have become the drug of choice for the treatment of schizophrenia and 
related disorders (Barbui et al., 2005). Clozapine on the other hand, is generally 
reserved for treatment-refractory patients because of its potential risk of 
agranulocytosis (Walker et al., 2004). Atypical antipsychotics are generally as 
efficacious as typical antipsychotics in reducing positive symptoms but less likely to 
cause extrapyramidal side-effects (Chue, 2006). In numerous studies, these newer 
generation of antipsychotics have also demonstrated a trend of superior efficacy in 
the management of a broader range of symptoms including negative, cognitive and 
affective symptoms (Lambert & Naber, 2004). Additionally, in a few studies 
involving limited number of atypical antipsychotics like clozapine, risperidone and 
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olanzapine, there is a tendency for patients to display improvement in quality of life 
(Awad, 2004a). 
However, the typical antipsychotics are still the prevalent medications 
prescribed for the treatment of schizophrenia in many low and middle-income 
countries (Choong et al., 2004). For instance, according to the Malaysian National 
Mental Health Registry (NMHR) report 2003-2004, a mere 13.3% of schizophrenia 
patients were prescribed with atypical antipsychotics while the majority were treated 
with typical antipsychotics (Gill et al., 2005). Compared to their predecessors, 
atypical antipsychotics have higher acquisition costs wherein the price of a unit dose 
of atypical antipsychotics reaching 10-25 fold higher than those of conventional 
antipsychotics (Tandon, 2006). Moreover, particularly for less developed countries, 
the price of antipsychotic is influenced by the currency exchange rates and market 
forces. These partially explained the astounding 61.8 % of the overall direct costs 
spent on medications in a study in Nigeria compared to a lower proportion of 1.1% 
to 9% paid by the high income countries (Knapp et al., 2004). Under consumption of 
more expensive antipsychotics in these countries is also limited by the low provision 
of resources for mental health services as well as out-of pocket payments by 
individuals (Dixon et al., 2006). In Malaysia, only 3% of the yearly health budget 
was provided for the expenditures of mental health including the acquisition of 
antipsychotic medications (Chee, 2009).      
Varying use of atypical antipsychotics among the nations is also affected by 
the uncertainties of whether the benefits of these medications are worth their 
additional costs (Haro et al., 2003a). Although there have been claims that atypical 
antipsychotics generate better health benefits which compensate for their higher 
acquisitions costs, there is no clear evidence to support that atypical antipsychotics 
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are more cost-effective than the typical antipsychotics (Polsky et al., 2006). 
Moreover, at least a number of atypical antipsychotics are associated with 
significantly greater risk for metabolic side-effects including weight gain, impaired 
glucose regulation, diabetes mellitus and dyslipidemia which have implications to 
treatment outcomes and costs (De Hert et al., 2006). Advantages of atypical 
antipsychotics on other outcomes like cognition, affect and quality of life also have 
not been extensively investigated and thus far their therapeutic benefits have been 
considered as modest and not substantial (Miyamoto et al., 2005). 
 
1.3 Quality of Life and Antipsychotic Medications  
 An array of outcome measures have been utilised to examine the health 
outcomes of schizophrenia or compare pharmaceutical treatment alternatives (Burns, 
2007). The Economic, Clinical and Humanistic Outcomes (ECHO) model has been 
proposed to describe health outcomes along three aspects; clinical consequences of 
medical intervention or illness such as symptom outcomes, economic impact 
regarding the amount spent or value for money associated with an intervention and 
humanistic outcomes like quality of life or functional status that captures the impact 
of disease or treatment on patient’s daily living (Mahmoud et al., 2002).         
 Over the past twenty years, there has been a rise in the investigation of 
quality of life (QoL) in general medicine, mainly in chronic disabling disorders 
(McKenna, 1997). Heightened interest in the QoL concept symbolizes the expansion 
of therapeutic outcome criteria that extends beyond traditional, physiological or 
biological measures. Furthermore, it reflects the modern image of health viewed 
from a bio-psychosocial standpoint that emphasizes on the patient’s subjective 
perspective of the disease or medical interventions (Naber et al., 2002). Nonetheless, 
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there is no universal definition of QoL while various terms such as ‘life satisfaction’, 
‘health status’, ‘functional status’ and ‘well being’ have been equated to it (Chan & 
Yu, 2004). The term ‘health-related quality of life’ (HRQoL) has been coined by 
researchers in the medical discipline to differentiate their area of research from the 
global concept of quality of life those of other field like social science (Bungay et 
al., 2005). While quality of life refers to an evaluation of every components of a 
person’s life, HRQoL includes aspects of life that are exclusively related to personal 
health and activities performed to maintain or improve health (Bungay et al., 2005).  
 Research in the HRQoL in schizophrenia commenced with growing concerns 
about the predicament of the chronically mentally ill patients living among the 
society following the deinstitutionalization movement in the USA in the 1970s 
(Revicki et al., 1999). Interest in the HRQoL assessment in schizophrenia declined 
thereafter as research was restricted by certain factors like lack of clarity on the 
conceptual models, scarcity of standardized measures for schizophrenia and qualms 
regarding the reliability of self-report in patients with schizophrenia (Gee et al., 
2003). The rapid development of new antipsychotic medications and the need to 
verify their therapeutic superiority in compensation for their relatively expensive 
acquisition costs has encouraged further interest in the use of HRQoL as an outcome 
measure in clinical trials (Awad et al., 1997a). Atypical antipsychotic medications 
collectively display greater efficacy in treating negative symptoms and cause fewer 
extrapyramidal effects which led to assumptions that these characteristics would 
translate into favourable HRQoL in patients (Montes et al., 2003).  
 There is no general consensus about the constituents of HRQoL, but many 
agreed that it is a multidimensional construct and mainly include the dimensions of 
physical functioning, social functioning, role functioning, mental health and general 
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health perceptions (Murdaugh, 1997). A few conceptual models of the interactions 
among the components of HRQoL in schizophrenia have been considered including 
the ‘clinical model’, the ‘mediation model’ and the ‘distress-protection model’ 
(Ristner et al., 2004a). Basic ‘clinical model’ by Awad et al. (1997b) defined 
HRQoL as one’s perception of the outcome interaction between symptoms, side-
effects, subjective responses to antipyschotics and psychosocial performances. On 
the other hand, ‘mediation model’ by Zissi et al. (1998) emphasized the significance 
of psychological processes in the HRQoL construct while ‘distress/protective 
model’ by Ritsner et al. (2002) postulated that HRQoL is an outcome of the 
interaction of an array of distress/clinical factors and protective factors in which 
HRQoL lessens if distress/clinical factors outweighed protective factors and vice 
versa (Ritsner et al., 2004a). 
Numerous HRQoL scales has been utilised in research involving 
schizophrenia patients. In general, these instruments are categorised as generic or 
disease-specific and available as self-rated or clinician-rated scale (Awad et al., 
1997a). Generic measures provide broader information on all aspects of life and 
permit comparisons with other diseases which are useful in facilitating health policy 
decisions and economic evaluations of medications and treatments (Konig et al., 
2007). Alternatively, disease-specific HRQoL instruments have the potential of 
being sensitive to changes to treatment effects (Karow et al., 2005). There is no 
consensus on the best scale to assess HRQoL in patients with schizophrenia (Karow 
et al., 2005a). The instrument of choice for HRQoL measurement depends on the 
purpose of its assessment (Bobes et al., 2005). As the generic and disease-specific 
instruments are deemed complementary, the use of both measures is recommended 
whenever practical (Konig et al., 2007). Health-related quality of life instrument for 
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patients with schizophrenia should also incorporate life domains highly relevant to 
those inflicted with the disease generated via in-depth qualitative interviews with the 
patients (McKenna, 1997). 
 Schizophrenia specific questionnaires like the Heinrichs-Carpenter Quality 
of Life Scale (QLS), the Drug Attitude Inventory (DAI) and the Subjective Well-
being under Neuroleptics (SWN-K) have been used to evaluate the effectiveness of 
antipsychotic medications on HRQoL, but the predominantly used scale is the QLS 
(Karow & Naber, 2002). Although it has historical values, the QLS is a clinician-
based measure that does not include the patients’ view of their quality of life and 
primarily designed to address negative symptoms in schizophrenia (Bobes et al., 
2005). Alternatively, the Schizophrenia Quality of Life Scale (SQLS) is a self-report 
measure, developed by Wilkinson et al., (2000) with contents that are highly 
relevant to people with schizophrenia derived from in-depth interviews with 
schizophrenic patients. The Schizophrenia Quality of Life Scale Revision 4 (SQLS-
R4) has been translated into 52 languages including the Malay language through 
standardized procedures and has been validated in several East Asian countries 
including Japan, Korea and Taiwan (Kaneda et al., 2002; Kim et al., 2006; Kuo et 
al., 2007). Testing of internal consistency and construct validity has also 
demonstrated that SQLS-R4 is a simple and reliable scale for measuring quality of 
life in patients with schizophrenia (Kaneda et al., 2002; Kim et al., 2006). 
 A few generic instruments such as the Medical Outcomes Study 36-Item 
Short Form Health Survey (SF-36), the World Heath Organization Quality of Life 
Instrument (WHOQOL) and the EuroQoL Group EQ-5D have been validated in 
patients with schizophrenia (Bobes et al., 2005). The EQ-5D is a self-administered, 
straightforward and short HRQoL that could be used to describe health profile, but 
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also preference-based valuation of HRQoL as weights for quality-adjusted life years 
(QALYs) in cost-utility analysis (Konig et al., 2007). It is the instrument of choice 
for the calculation of QALYs and has been validly translated into no less than 30 
languages including the Malay language (Konig et al., 2007). The EQ-5D has been 
used in population health surveys in numerous medical disorders and economic 
evaluation of drug or health-care interventions for a specific health condition 
(Willige et al., 2005).  
 Studies on the effects of antipsychotics on HRQoL in schizophrenia patients 
have generated contradictory findings. Favourable HRQoL for patients treated with 
atypical antipsychotics against typical antipsychotics have been documented but not 
consistently reproduced by other trials (Awad & Voruganti, 2004a). Although there 
is a likely trend for the newer generation of antipsychotics to surpass the 
conventional antipsychotics in improving HRQoL, comparisons across studies are 
complicated because different conceptual models, study designs, HRQoL 
instruments and time frame were applied on various clinical populations (Pinikahana 
et al., 2002). Moreover, not many studies include atypical antipsychotic drugs other 
than olanzapine, clozapine and risperidone (Awad & Voruganti, 2004a). 
 Socio-demographic factors and clinical conditions have also been suggested 
to affect HRQoL (Chan & Yu, 2004). In a few studies, young patients, married 
people, women and less educated individuals with schizophrenia have reported 
better HRQoL (Gladis et al., 1999). Alternatively, presence of intense positive and 
negative symptoms as well as longer duration of illness has been associated with 
poorer HRQoL (Chan & Yu, 2004; Konig, et al., 2007). The impact of 
sociodemographic and clinical factors however, varies from one study to another 
(Chan & Yu, 2004). 
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1.4  Pharmacoeconomic Evaluation of Antipsychotic Treatment 
 With the introduction of atypical antipsychotics into the standard practice, 
there is growing concern over the costs of treatment for schizophrenia (Revicki et 
al., 1999). Although acquisition costs of antipsychotic medications constitute a small 
fraction of direct treatment costs, the comparatively higher acquisition costs of 
atypical antipsychotics than the established therapy and its increased consumption 
have somewhat contributed to the rise in drug expenditure (Basu, 2004). 
Considering the increased use of limited health care resources, assessment of the 
incremental value of these novel antipsychotics is crucial for public policy decisions 
and other resource allocations decisions (Polsky et al., 2006). Pharmacoeconomic 
studies investigate the impact of different antipsychotic drugs on medical costs and 
health benefits providing insight in assessing the value of new antipsychotic 
medications and facilitating decision making for the efficient allocation of health 
care resources (Basu, 2004). Cost-effectiveness analysis (CEA) is the prevalent 
method among the several types of pharmacoeconomic analyses used in the medical 
literature to address such issue (Basu, 2004). 
 In CEA, all medical resources consumed (costs) and relevant health 
outcomes (consequences) are compared between different treatment alternatives to 
determine the average cost-effectiveness (C/E) ratio (average cost per outcome) for 
each treatment alternative. Incremental (ICER) ratio indicates the cost to produce a 
unit increase in an outcome for a new treatment relative to an existing alternative 
treatment (Skrepnek, 2005). Cost assessments are similar across different methods 
of economic analyses, but the outcome measure differs and for the CEA of 
antipsychotic medications, the outcome is expressed in natural units including 
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extrapyramidal symptom-free months, psychiatric symptoms, disability-free days 
and hospitalizations avoided (Polsky et al., 2006). 
 Given the multitude of outcome measures that were used in the cost-
effectiveness studies, it is difficult to compare the efficacy of various treatments 
with different outcomes or measure different treatments against one another when 
they each perform differently with certain outcome measures (Mangalore, 2000). 
Considered by some as an adaptation of CEA, cost-utility analysis (CUA) was 
developed to address the problem of comparing treatment interventions with 
different health outcomes (Dernovsek et al., 2007). CUA is more appropriate when 
HRQoL is the important outcome, when both quantity and quality of life are affected 
by treatment and when interventions being compared have extensive possible health 
outcomes (Coons & Kaplan, 2005). In this form of economic evaluation, HRQoL 
outcomes are adjusted for patient preferences or utility and expressed as a single 
composite measure typically quality-adjusted life years (QALYs) (Proschyn et al., 
2000). QALY supplies a common measure to evaluate the extent of health benefits 
achieved from a variety of treatments in terms of HRQoL as well as quantity of life 
(Neumann, 1999).  
  Health state preferences for the calculation of QALY may be assessed 
directly using a variety of techniques including standard gamble, rating scale, time-
trade off or indirectly using preference-based HRQoL instruments also known as 
multi-attribute health status classification systems like the Quality of Well-Being 
Scale (QWB), the Health Utilities Index (HUI) and the EuroQol Group’s EQ-5D 
(Coons & Kaplan, 2005). The EQ-5D is one of the commonly used instruments for 
assessing QALYs (Patterson et al., 1999). It provides standard HRQoL assessments 
and concurrently allows the assignment of patients’ preferences without having 
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recourse directly to the standard yet complex techniques like standard gamble or 
time-trade off (Prieto et al., 2004). 
 In a recent literature review of randomized clinical trial-based cost-
effectiveness studies of antipsychotics, Polsky et al. (2006) concluded that thus far 
there is no clear evidence to suggest that atypical antipsychotics generate cost 
savings or are cost-effective for schizophrenia treatment in general.  These cost-
effectiveness studies have limited applicability as their validity was profoundly 
affected by inappropriate methods of measurement, analysis and study design while 
only a few studies employ the cost-utility analysis approach (Polsky et al., 2006). 
Moreover, particularly in developing countries, there are very few economic 
evaluations on antipsychotic drugs to facilitate policy-makers and clinicians in the 
selection of the most appropriate therapy (Shah & Jenkins, 2000). Extrapolation of 
the economic evaluations of alternative antipsychotics in one country to another may 
not be feasible as differences in price levels, supply of specific services and the 
structure of mental health services may affect treatment effectiveness as well as 
service use and therefore costs (McCrone, 2007).  
 
1.5      Clinical Outcome Domains in Schizophrenia Treatment 
           Symptoms of disease, treatment burden in terms of side-effects and treatment 
adherence are among the target outcome domains considered in the assessment of 
clinical effectiveness of antipsychotic medications (Naber & Vita, 2004). Positive 
symptoms (e.g. hallucinations, delusions) of schizophrenia were the conventional 
measure of effectiveness in drug investigations, but better understanding on the role 
of other symptom domains of negative (e.g. social withdrawal, decreased 
motivation), cognitive (e.g. memory impairment, attention deficits) and affective 
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symptoms (e.g. depression, mood swings) have positioned them as key treatment 
outcomes as well (Nasrallah et al., 2005). Negative, cognitive and affective 
symptoms have been suggested to be associated with functional outcomes of 
schizophrenia and their improvements were deemed important for good long-term 
prognosis (Naber & Vita, 2004). 
In general, atypical antipsychotics were comparable to typical antipsychotics 
regarding their efficacies against psychotic symptoms (Lublin et al., 2005). The 
increasing evidence on the greater efficacy of atypical antipsychotics in the 
treatment of negative symptoms are limited by uncertainties of the causal 
relationship between atypical antipsychotics and negative symptoms as well as their 
modest treatment effects (Miyamoto et al., 2005). There has been a trend for atypical 
antipsychotics to exert improvement in cognitive functioning, but the effects of 
atypical antipsychotics on cognition have not been widely studied (Miyamoto et al., 
2005). The Clinical Global Impression-Schizophrenia (CGI-SCH) scale; a 
modification of the Clinical Global Impression (CGI) scale is among the most 
commonly used symptom rating scales that measures various symptoms in 
schizophrenia and is applicable for both observational study and regular clinical 
practice (Mortimer & Al-Agib, 2007). 
 The side effects of antipsychotic medications are wide-ranging and have 
been associated with physical and psychological impairment in patients with 
schizophrenia (Ritsner et al., 2002). The presence of side effects has also been 
linked to reduced adherence to treatment regimens (Miyamoto et al., 2005). Atypical 
antipsychotics generally produce fewer extrapyramidal side-effects (EPS) than 
typical antipsychotics, but this newer generation of antipsychotics are associated 
with a different range of adverse effects including non EPS side-effects typically 
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weight gain, sexual difficulties, sedation and amenorrhoea (Weiden & Miller, 2001). 
Many scales for the assessment of antipsychotic side-effects were particularly 
developed to monitor EPS (for example the Barnes Akathisia Rating Scale, the 
Simpson-Angus Extrapyramidal Side Effects Scale and the Abnormal Involuntary 
Movement Scale) and their use also requires special expertise (Weiden & Miller, 
2001). Alternatively, the Approaches to Schizophrenia Communication Clinician 
Interview Version (ASC-C) include all the common and troubling antipsychotic 
side-effects and check for subjective distress instead of objective severity of side-
effects (Nasrallah et al., 2005).      
Adherence to antipsychotic medication is pertinent to attaining effective 
symptom controls in schizophrenia (Dolder et al., 2002). Non-adherence to 
prolonged antipsychotic treatment has been linked to greater risk of relapse, frequent 
hospital admissions and emergency visits (Gilmer et al., 2004). In research, non-
adherence to antipsychotic medications may also lessen the chance to distinguish 
between treatment outcomes, thus can influence the study validity by inflating the 
risk of false negative results (Hess et al., 2006). Since atypical antipsychotics cause 
minimal EPS compared to typical antipsychotics, better medication adherence 
behavior was anticipated among patients on atypical antipsychotics (Dolder et al., 
2002). However, very few studies compared medication adherence between typical 
and atypical antipsychotics. Findings from these studies were also contradictory in 
which not all found greater medication adherence among patients receiving atypical 
antipsychotics (Awad, 2004). 
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1.6 Problem Statement 
 Economic evaluations of treatment interventions in mental disorders were 
generally limited particularly, for developing countries (WHO, 2001). In Malaysia, 
there is paucity of research data including economic evaluations in mental 
conditions necessary for policy-makers and clinicians to make informed choices 
(Deva, 2004). According to the Malaysian National Medicines Use Survey (NMUS) 
2005, psycholeptics (a group of medications that produces calming effects on 
patients including antipsychotics) were among the 30 widely utilized medications, 
but there is inadequate information on the epidemiology and the treatment of the 
medical condition for which these medications are indicated (Sarojini et al., 2008).  
 This observational study with prospective design will examine and compare 
the effectiveness, cost-effectiveness and cost-utility of typical and atypical 
antipsychotic drugs in schizophrenia patients receiving outpatient treatment in a 
teaching hospital in Kuala Lumpur, Malaysia. This research will obtain data on the 
outcomes of different types of antipsychotics in terms of clinical effectiveness, 
HRQoL and economic consequences by cost-effectiveness and cost-utility analyses 
to determine the relative benefits of atypical antipsychotics in regular clinical 
practice to facilitate clinical decision makings and prudent allocations of scarce 
healthcare resources (Basu, 2004).                   
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1.7 Purpose Statement 
  The purpose of this study was to determine whether there is a significant 
difference between schizophrenia outpatients undergoing treatment with typical 
antipsychotics and those on treatment with atypical antipsychotic adjusted for any 
difference in demographics, illness and treatment related factors in the areas of:  
(i) HRQoL scores as measured by the disease-specific Schizophrenia Quality of Life 
Scale Revision 4 (SQLS-R4),  
(ii) HRQoL scores as measured by generic instrument, the EQ-5D, 
(iii) Cost-effectiveness from a societal perspective,  
(iv) Cost-utility from a societal perspective, 
(v) Clinical outcomes in terms of symptom severity as measured by the Clinical 
Global Impressions-Schizophrenia (CGI-SCH) severity scale, side-effects as 
measured by the Approaches to Schizophrenia Communication Clinician Interview 
Version (ASC-C) side-effect checklist and antipsychotic adherence as measured by 
prescription refills.  
(vi) The study also intended to examine the relationships between HRQoL and 
clinical outcomes of symptom severity, side-effects and treatment adherence.    
     
1.8 Rationale of Study  
 The concept of ‘health’ has been historically viewed as freedom from 
disease. However, in 1948 its meaning was expanded by the World Health 
Organization (WHO) to include complete physical, mental and social well-being 
(Bungay et al., 2005). Over the past two decades the therapeutic goal for many 
chronic and disabling medical conditions like diabetes and arthritis has been 
broadened to include maintaining or restoring quality life. Likewise in psychiatry, 
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the concept of outcome has been extended beyond symptom improvement to 
incorporate HRQoL, an important measure of therapeutic effectiveness and thus has 
become an important element in the economic evaluations (Bobes et al., 2005).  
 In schizophrenia, antipsychotics are significant contributors to HRQoL. A 
study on clinically stabilized schizophrenic patients demonstrated that 50% of the 
variance in patient ratings of HRQoL was explained by severity of clinical 
symptoms and subjective distress by adverse effects of antipsychotics such as 
akathasia and neuroleptic dysphoria (Revicki et al., 1999). Hence with the 
introduction of new antipsychotics, there is a need to evaluate the impact of different 
antipsychotics on HRQoL. 
 Schizophrenia also imposes a great economic burden on society as a result of 
its prevalence, early onset and chronicity (Procyshyn et al., 2000). In a recent 
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) in the United 
States, much of the costs of treatment of chronic schizophrenia are driven by the 
costs of drugs (Freedman et al., 2006). Thus cost-outcome evaluations are 
particularly important as they allow comparisons of the potential costs and 
consequences of various treatments to allow judicious use of scarce resources (Shah 
& Jenkins, 2000).  
 Cost-utility analysis is based on values that people place on different health 
outcomes and captures in single measure, improvements in HRQoL and increases in 
life expectancy. It is the most informative type of economic analysis that provides 
the necessary data for comparing alternative medical treatments within and across 
different disease categories. It is also the approach to economic evaluation 
recommended by the Panel on Cost-Effectiveness in Health and Medicine of the 
United States Public Health Service (USPHS), the committee which provide 
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recommendations for conducting standard cost-effectiveness studies (Singh et al., 
2001, Coons & Kaplan, 2005). 
 Most HRQoL outcome studies of antipsychotic drugs have been performed 
on Caucasian populations and their application to Asian community may be limited 
as subjective HRQoL are influenced by the cultural background of individuals 
(Kongsakon et al., 2006). Very few studies have explored the efficacy of 
antipsychotic medications using utility or preference based measures of HRQoL 
(Patterson et al., 1999). Economic studies in psychiatric conditions were rare in 
developing countries and the very few available studies were mainly cost-of-illness 
and cost-effectiveness studies (Shah & Jenkins, 2000). The application of economic 
analysis from one country to another is not always possible considering that many 
factors including local health and social service characteristics, culture, family 
lifestyles, religion, stigma attached to mental illness, local demography and local 
epidemiology of mental disorders may affect the use and efficacy of any new 
interventions (Shah & Jenkins, 2000). 
 In Malaysia, the few available documented quality of life studies in patients 
with schizophrenia centred on the impact of demographic profiles and community-
based mental health programmes on the general quality of life (Mubarak et al., 2003; 
Mubarak, 2005; Mubarak, 2006). There is little documentation on the cost-
effectiveness or cost-utility studies of different types of antipsychotics among 
schizophrenia patients undergoing regular out-patient care. Only two local studies 
were identified; a study by Chee (2009) that compared the HRQoL outcomes 
between typical and atypical antipsychotics in schizophrenic outpatients and Hatim 
et al. (2009) that evaluated the costs involved in switching treatment from typical 
antipsychotic to the atypical antipsychotic, risperidone. Thus, more studies need to 
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be conducted in Malaysia to determine the value of the newer generations of 
antipsychotics in terms of HRQoL, clinical and economic outcomes to add to the 
existing scarce data.    
        
1.9 Potential Contribution of the Study Findings 
 According to the National Mental Health Registry (2005), only 13% of 
registered schizophrenia cases from 28 Ministry of Health hospitals and 4 University 
hospitals were started on atypical antipsychotics. A study of drug utilization in 
Malaysia, the Malaysian Statistics on Medicine (2006) also found similar 
prescribing pattern. Low utilization of this newer generation of antipsychotic was 
attributed to its higher price. Public health sector is heavily subsidized by the 
government but escalating costs of health care including procurement of 
pharmaceuticals has to a certain extent limited access to medicines (Babar et al., 
2007).  
 In order to ensure sustainability of Malaysian healthcare system, a new 
mechanism of health care financing known as The National Health Financing 
Scheme was considered during the Fourth Malaysian Plan (1981-1985) and in view 
of ever-increasing health care costs was further highlighted in the Ninth Malaysian 
Plan 2006-2010 (WHO, 2008). For this proposed scheme, the provision of 
pharmaceuticals will be managed through a drug procurement system where patients 
have to pay a certain amount in order to obtain prescribed medicines (Choe & 
Damis, 2010).  
 Local research on the HRQoL, clinical and economic outcomes of different 
types of antipsychotics thus, will provide information on both costs and outcomes of 
alternative antipsychotics to aid drug regulatory authorities in making decisions on 
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the availability and access of different antipsychotic alternatives for the imminent 
drug delivery system. Clinical, humanistic and economic outcomes of antipsychotic 
treatment which include the interest of patients also facilitate understanding among 
patients and their payers on ‘value for money’ of alternative antipsychotics as well 
as improve clinicians’ appreciation of antipsychotic consequences on patient’s 
psychosocial well-being to plan for individual clinical care and improve the existing 
practice of care.       
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CHAPTER 2 
  
GENERAL METHODOLOGY 
 
2.1 Study Objectives 
2.1.1 General Objectives  
 The objectives of the study were to determine and compare the impact of 
different types of antipsychotic maintenance treatment on comprehensive measurement 
parameters; clinical, humanistic and economic outcomes in routine clinical practice 
over a period of time adjusted for socio-demographic, clinical or treatment differences. 
 
2.1.2 Specific Objectives 
(i) To evaluate and compare HRQoL outcomes of atypical versus typical 
 antipsychotic drugs using schizophrenia specific HRQoL instrument, the 
 SQLS- R4 and generic HRQoL instrument, the EQ-5D. 
(ii) To evaluate and compare the clinical outcomes of symptom severity using  the 
            CGI-SCH, side-effects by the ASC-C and treatment adherence using 
 prescription refills of atypical versus typical antipsychotic drugs. 
(iii) To estimate the cost-effectiveness and cost-utility ratios of atypical 
 antipsychotics and typical antipsychotics from the perspective of society. 
(iv) To determine the incremental cost-effectiveness ratios for atypical 
 antipsychotics to typical antipsychotic drugs. 
